Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆÄ³ªÁø     (Date : 2011-08-26 18:31:16)
Á¦¸ñ [³í¹®] [Microarray]Peptide nucleic acid-based (PNA) array for the antigenic discrimination of canine parvovirus
³»¿ë

Research in Veterinary Science 2011
DOI : 10.1016/j.rvsc.2011.06.003


Peptide nucleic acid-based (PNA) array for the antigenic discrimination of canine parvovirus

Dong-Jun An, Wooseog Jeong, Hye-Young Jeoung, Myoung-Heon Lee,
Jee-Yong Park, Ji-Ae Lim, Bong-Kyun Park

Abstract

A novel peptide nucleic acid (PNA)-based array was developed for use in ante-mortem antigenic typing discrimination in dogs with canine parvovirus (CPV). Cyclic benzothiazole-2-sulfonyl PNA monomers were synthesized that recognized GTA (CPV-2) and TAT (CPV-2a, -2b and -2c) at the nt 913-915 positions, and AAT (CPV-2 and CPV-2a), GAT (CPV-2b), and GAA (CPV-2c) at the nt 1276-1278 positions of the VP2 gene. The detection limits for aa 305 and aa 426 of the VP2 proteins belonging to the four CPV antigenic types were determined optically to be 40-2000 DNA copies, and the optimal cut-off fluorescence signaling value was fixed at 5000. The PNA array described here was developed from 135 field dog fecal specimens and had 89.8% (62/69) sensitivity and 90.4% (66/73) specificity compared with a real-time PCR using the TaqMan assay, a gold standard method. This CPV PNA array could be used together with MGB probe assays as an attractive novel tool for ante-mortem antigenic typing discrimination.

Keywords : CPV, PNA, MGB probe


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆÄ³ªÁø 32779
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆÄ³ªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆÄ³ªÁø 44162
   46           [³í¹®] [2015]Simultaneous genoty.. ÆÄ³ªÁø 6867
   45           [³í¹®] [2014]Simultaneous diagno.. ÆÄ³ªÁø 34916
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆÄ³ªÁø 13861
   43           [³í¹®] [2013]Detection of EGFR m.. ÆÄ³ªÁø 1596
   42           [³í¹®] [2013]Detection and compa.. ÆÄ³ªÁø 6254
   41           [³í¹®] [2013]Detection of BRAF V.. ÆÄ³ªÁø 6690
   40           [³í¹®] [2013]Comparison of Direc.. ÆÄ³ªÁø 54807
¢º           [³í¹®] [Microarray]Peptide nucle.. ÆÄ³ªÁø 22799
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆÄ³ªÁø 65535
   37           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆÄ³ªÁø 3984
   36           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆÄ³ªÁø 50580
   35           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆÄ³ªÁø 1746
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆÄ³ªÁø 29185
   33           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆÄ³ªÁø 17704
   32           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆÄ³ªÁø 33825
   31           [³í¹®] [ÆÄ³ªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆÄ³ªÁø 4281
   30           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆÄ³ªÁø 4516
 

< 1 2 3 >